drugset / Trial / NCT07681089
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Phase 2
Not yet recruiting
4 enrolled
Kiminori Kimura, MD
Japan Agency for Medical Research and Development · collabOhara Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-11-30
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRI-724 | Small molecule | 280 mg/m2 | Intravenous |